Pien-Tze-Huang attenuates neuroinflammation in cerebral ischemia-reperfusion injury in rats partially through the TLR4/NF-κB/MAPK pathway

Xiao-qin Zhang  
Fujian University of Traditional Chinese Medicine

Qing Zhang  
Fujian University of Traditional Chinese Medicine

Li-li Huang  
Fujian University of Traditional Chinese Medicine

Ming-zhen Liu  
Fujian University of Traditional Chinese Medicine

Zai-xing Cheng  
Fujian University of Traditional Chinese Medicine

Yan-fang Zheng  
Fujian University of Traditional Chinese Medicine

Wen Xu  
Fujian University of Traditional Chinese Medicine

Jin-Jian Lu  
University of Macau

Jian Liu  
Fujian University of Traditional Chinese Medicine

Mingqing Huang  
Fujian University of Traditional Chinese Medicine  
https://orcid.org/0000-0002-2853-1087

Research

Keywords: Ischemic stroke, Inflammation, Pien-Tze-Huang, TLR4, NF-κB, MAPK

DOI: https://doi.org/10.21203/rs.3.rs-226254/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Background

Pien-Tze-Huang (PTH), one of the most famous traditional Chinese medicines in China, is traditionally applied to treat various inflammation-related diseases including stroke. However, literature regarding the anti-inflammatory effects and possible mechanisms of PTH in ischemic stroke is unavailable. This study intended to investigate the anti-inflammatory effects of PTH against cerebral ischemia-reperfusion injury and clarify its potential molecular mechanisms.

Methods

Cerebral ischemia-reperfusion injury was induced through transient left transient middle cerebral artery occlusion (MCAO) in male rats receiving oral pretreatment with PTH (180 mg/kg) for 4 days. TLR4 antagonist TAK-242 (3 mg/kg) was injected intraperitoneally at 1.5 h after MCAO. Magnetic resonance imaging, hematoxylin–eosin staining, RT-PCR, western blot, and immunofluorescence methods were used to studied the effect and mechanism of PTH against ischemic stroke.

Results

PTH treatment reduced cerebral infarct volume, improved neurological function, and ameliorated brain histopathological damage in MCAO rats. In addition, it markedly suppressed a variety of inflammatory responses as evidenced by the reduced mRNA levels of IL-1β, IL-6, TNF-α and MCP-1; the inhibition of microgli and astrocyte activations; and the decreased protein expressions of iNOS and COX-2 in injured brains. Moreover, PTH down-regulated the protein expressions of TLR4, MyD88, and TRAF6; reduced the expression and NF-κB; and lowered the protein expressions of p-ERK1/2, p-JNK, and p-p38. Similar effects were observed in the TAK-242 treated group. However, TAK-242 did not significantly reinforce the anti-inflammatory effects of PTH.

Conclusion

PTH could attenuate neuroinflammation, improve neurological function, and alleviate brain injury in MCAO rats, and its potential mechanisms are partly connected to inhibition of neuroinflammation involving the TLR4/NF-κB/MAPK signaling pathway.

Background

Ischemic stroke, a common and terrible disease worldwide, often results in high rates of death and disability [1]. It occurs when the cerebral artery is suddenly blocked followed by a series of pathological events, such as inflammatory response, calcium influx, excitatory toxicity, oxidative stress, and cell
apoptosis[2, 3]. Currently, available therapeutic agents for this disease are limited and exhibit poor clinical outcomes. Among these limited agents, tissue plasminogen activator is the only one approved by the FDA; however, its clinical application is severely restricted due to its narrow therapeutic window and high risk of intracerebral hemorrhage [4, 5]. Therefore, therapeutic agents with increased effectiveness and safety are urgently needed for preventing or treating ischemic stroke.

Accumulating evidence shows that inflammation plays a crucial role in different periods of ischemic stroke, which not only results in brain injury but is also closely associated with functional recovery [6, 7]. Toll-like receptors (TLRs), especially Toll-like receptor 4 (TLR4), play an integral part in the inflammatory cascade reaction after cerebral ischemia injury [8, 9]. TLR4 is swiftly stimulated by various endogenous ligands [10] and subsequently activates protein myeloid differentiation primary response gene 88 (MyD88) after cerebral ischemia [11]. As a result, two important signaling pathways, namely nuclear factor-κB (NF-κB) and mitogen-activated protein kinases (MAPKs), are activated to produce proinflammatory cytokines and further aggravate tissue damage [12]. In addition, the inhibition or knockout of TLR4 can attenuate inflammatory responses and protect against ischemic brain injury in rodent [13, 14]. Thus, targeting the TLR4/ NF-κB/MAPK signal pathway and its mediated inflammation is a potential therapeutic direction against ischemic stroke.

Traditional Chinese medicine (TCM) has attracted extensive attention for preventing and treating cerebrovascular diseases based on its unique theoretical system and comprehensive therapeutic effects. As one of the most famous TCM preparations in China, Pien-Tze-Huang (PTH) is composed of Radix et Rhizoma Notoginseng, Moschus, Calculus Bovis, and Snake Gall, which was first prescribed in 1555 AD. It is commonly applied to treat various inflammation-related diseases including stroke attributed to its traditional clearing fever and detoxifying, namely anti-inflammatory effect [15]. There are several pharmacological studies investigated the protective and therapeutic effects of PTH against ischemic stroke, which confirmed its traditional application in stroke therapy [16, 17]. Our recent study demonstrated that pretreatment with 180 mg/kg PTH can decrease infarct volume and alleviate neurological deficits in MCAO rats by inhibiting the mitochondria-mediated apoptotic pathway and modulating the AKT/glycogen synthase kinase-3 beta pathway [18]. Importantly, the up-regulated inflammatory cytokines including TNF-α, IL-6 and IL-1β in injured brain were also remarkably suppressed by PTH, indicating that the anti-inflammatory effect may play part in the anti-stroke potency of PTH [18, 19]. Moreover, recent studies have revealed the anti-inflammatory effects of PTH in hepatitis through regulating NF-κB pathway [20, 21]. However, the detailed relationship between the anti-inflammatory and anti-stroke effects of PTH remains unclear.

Collectively, we hypothesized that the effect of PTH on cerebral ischemia-reperfusion injury is ascribed to suppression of neuroinflammation. In the present study, MCAO rats were applied to explore whether PTH attenuate neuroinflammation in cerebral ischemia-reperfusion, and to further illustrate the possible molecular mechanisms involved in the TLR4/NF-κB/MAPK signaling pathway.

Materials And Methods
Reagents

TAK-242 (HY-11109) was obtained from MedChemExpress (Monmouth Junction, NJ, USA). TLR4 (sc-293072), MyD88 (sc-74532), IκBα (sc-1643), and NF-κB p65 (sc-8008) primary antibodies were provided by Santa Cruz Biotechnology (Dallas, TX, USA). COX-2 (12282), GFAP (3670), p38 (8690), JNK (9252), ERK1/2 (9102), p-EEK1/2 (Thr202/Tyr204) (9101), and GAPDH (2118) primary antibodies were provided by Cell Signaling Technology (Danvers, MA, USA). iNOS (ab3523) and TNF receptor-associated factor 6 (TRAF6, ab33915) primary antibodies were provided by ABCAM (Cambridge, MA, USA). Each secondary antibody was provided by Thermo Fisher Scientific (Rockland, IL, USA).

PTH capsules were purchased from Zhangzhou PTH Pharmaceutical Co., LTD. (Zhangzhou, China). In accordance with our reported UPLC–MS/MS method [22], 21 characteristic compounds (taurine, malic acid, citric acid, cholic acid, hyodeoxycholic acid, ursodeoxycholic acid, chenodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, tauroursodeoxycholic acid, glycodeoxycholic acid, glycocholic acid notoginsenoside R1, ginsenosides Rg1, Rb1, Re, Rf, Rd, Rg2, Rg3, Rh1, and muscone) in the PTH capsules were accurately quantified, and the total content of those compounds was 183.73 mg/g.

Animals

Male Sprague–Dawley rats weighing 230–260 g were provided by the Guangdong Experimental Animal Center (Guangzhou, no. SYXK-2019-0007). Animals were provided food and water ad libitum under SPF conditions at the temperature of 24°C ± 1°C and relative humidity of 60% ± 5%. All animal experiments were conducted with the approval of the Animal Care and Use Committee of Fujian University of Traditional Chinese Medicine.

Preparation of the middle cerebral artery occlusion model

The transient middle cerebral artery occlusion (MCAO) model was established in accordance with our previous protocol [23]. Briefly, male SD rats were anaesthetized with 5% isoflurane (Shenzhen, China) and maintained with 2% isoflurane. The left common, external, and internal carotid arteries were separated. A 0.38 mm nylon suture with a L3800 silicon-coated tip (Guangzhou, China) was carefully inserted into the internal carotid artery from the external carotid artery to occlude the middle cerebral artery. After occlusion for 1.5 h, the nylon suture was withdrawn to induce reperfusion. Sham rats were subjected to the same procedure without inserting the nylon suture into the MCAO.

Drug administration

Experiment 1: After adaption for 7 days, the rats were randomly allocated to three groups (n = 12): (1) Sham group: sham rats intragastrical (i.g.) administered 0.5% CMC-Na (10 mL/Kg); (2) MCAO group, MCAO rats i.g. administered 0.5% CMC-Na (10 mL/Kg); (3) MCAO + PTH group, MCAO rats i.g. administered PTH (10 mL/Kg). PTH was dissolved in 0.5% CMC-Na (18 mg/mL) and administered at the dose of 180 mg/kg once a day for 4 days before MCAO as previously described [18].
Experiment 2: After adaption for 7 days, animals were randomly divided into five groups (n = 6): (1) Sham group: sham rats i.g. administered 0.5% CMC-Na; (2) MCAO group, MCAO rats i.g. administered 0.5% CMC-Na; (3) MCAO + PTH group, MCAO rats i.g. administered PTH (180 mg/Kg); (4) MCAO + TAK-242 group, MCAO rats intraperitoneal (i.p.) administered TAK-242 (3 mg/kg); (5) MCAO + PTH + TAK-242 group, MCAO rats i.g. administered PTH (180 mg/Kg) and i.p. administered TAK-242 (3 mg/kg). TAK-242, an antagonist of TLR4, was dissolved in 10% DMSO and administered at the dose of 3 mg/kg at 1.5 h after MCAO. The other experimental conditions were the same as those described above.

Neurological deficit evaluation

In accordance with the reported procedures and criteria [18], the neurological deficit condition of each rat was evaluated blindly at 24 h after reperfusion.

Infarct volume measurement

Magnetic resonance imaging (MRI) test was used to determine the infarct volume as follows: A rat was anesthetized with 5% isoflurane and fixed in the animal cradle with its head inside the horizontal magnet bore of a BioSpec 70/20 USR 7.0 T MRI scanner (Bruker BioSpin, Ettlingen, Germany). Then, the coronal plane image was prescribed beginning at 3 mm behind the olfactory bulb. T2WI scans were performed with a turbo-rapid acquisition relaxation enhancement sequence. All images were obtained with the repetition time of 4200 ms, echo time of 55 ms, field of view of 32 × 32, matrix size of 256 × 256, slice thickness of 1 mm, and number of slices of 21. Image J software was used to calculate the infarct volume.

Hematoxylin–eosin staining

Each rat was anesthetized with 5% isoflurane, and its heart was perfused successively with saline and 4% paraformaldehyde. Then, its brain was removed, fixed, dehydrated, and embedded. The brain was cut into 5 µm thick sections and stained with hematoxylin and eosin (Beyotime, Shanghai, China). Finally, the sections were photographed under a DMi8 light microscope (Leica, Wetzlar, Germany).

qRT-PCR analysis

Ischemic brains were removed from deeply anesthetized rats at 24 h after reperfusion. Total RNA was extracted by using Trizol (Invirtogen) and reverse transcribed into cDNA with a Superscript First-Strand Synthesis System (Life Technologies, Grand Island, NY). Quantitative analysis was performed by using SYBR Green real-time PCR master mix (Life Technologies). GAPDH was used as the internal control in this study. The PCR primer sequences are listed as follows:

IL-1β Forward: 5’-GTGTTTTTCTCTCCTGCTCTGAT-3’
Reverse: 5’-GCTGCCTAATGTCCCCTTGAAT-3’

IL-6 Forward: 5'-CTGTCTGACCCATGTGAGCTG-3'
Reverse: 5'-TTTGTCGTTGCTTGTCTCTCCTT-3'

TNF-α Forward: 5'-ATGGGCTCCCTCTCATCAGT-3'

Reverse: 5'-GCTTGGTGGTTTGCTACGAC-3'

MCP-1 Forward: 5'-CAGGTCTCTGTACGCTTCT-3'

Reverse: 5'-GTAGTTTCTCCAGCCGACTCA-3'

GAPDH Forward: 5'-CAACGGGAAACCCATCACCA-3'

Reverse: 5'-ACACGGAAACCCATCACCA-3'

**Immunofluorescent staining**

Each brain was removed and embedded in paraffin as described above. After dewaxing and rehydration, each brain section (5 µm) was subjected to antigen retrieval solution for 15 min in a microwave oven and then blocked with 5% BSA containing 10% goat serum for 2 h. It was incubated overnight at 4°C with mouse monoclonal anti-NF-κB p65 antibody (1:100) or anti-Iba-1 antibody (1:300) diluted in the blocking solution. Subsequently, it was washed with PBST and incubated with FITC-conjugated goat antimouse IgG (1:200) for 1 h at 25°C. The nuclei were counterstained with DAPI (Beyotime) and cover-slipped. Finally, the immunofluorescent images were captured under a DMi8 microscope (Leica) and magnification of 200×. The number of NF-κB p65 or Iba-1-positive cells in five similar fields of the ipsilateral cortex from three sections per rat was counted by an investigator who was blinded to the treatment.

**Western blot analysis**

Proteins were extracted from brain tissues by using RIPA lysis buffer. BCA Protein Assay kit (Beyotime, Shanghai, China) was used to measure the protein concentration of each sample. Western blot analysis was conducted in accordance with our previous study [18]. In brief, each protein sample (30 µg) was separated through SDS-PAGE then transferred and blocked. Primary antibodies against TLR4 (1:500), MyD88 (1:500), TRAF6 (1:5000), IκBα (1:500), NF-κB p65 (1:500), p38 (1:1000), p-p38 (1:1000), JNK (1:1000), p-JNK (1:1000), ERK1/2 (1:1000), p-ERK1/2 (1:1000), COX-2 (1:1000), iNOS (1:500), GFAP (1:1000), and GAPDH (1:1000) were used. GAPDH was used as a control. Images were visualized by using ChemiDoc XRS + imaging system (Bio-Rad, Hercules, CA), and the target bands were scanned and analyzed quantitatively by using Image J software.

**Statistical analysis**

Data were expressed as means ± SEM and analyzed with SPSS software (version 20.0). One-way AVONA was used when the data conformed to normal distribution, whereas Kruskal–Wallis test or Mann–Whitney test was used when the data conformed to non-normal distribution. p < 0.05 was defined as statistically significant.
Results

**PTH decreased cerebral infarct volume and improved neurological deficits in MCAO rats**

MRI results (Fig. 1A and B) showed that relative to the Sham treatment, MCAO modeling induced remarkable increases in the cerebral infarct volume ($p < 0.01$), whereas PTH treatment significantly reduced cerebral infarct volume ($p < 0.05$). Similarly, as shown in Fig. 1C, MCAO modeling also resulted in worse neurological deficit compared with the Sham treatment ($p < 0.01$), and this deficit was markedly improved after PTH administration ($p < 0.05$). These data indicated that PTH could alleviate ischemia-induced brain injury in MCAO rats.

**PTH ameliorated brain histopathological damage in MCAO rats**

HE staining results (Fig. 2) showed that the cortical neurons of the Sham group were arranged regularly and had clear, well-stained structures, indicating the absence of histopathological changes. Compared with those of the Sham group, the cortical neurons of the MCAO group exhibited obviously disordered arrangement, nuclear shrinkage, and dark staining. However, PTH administration significantly attenuated the pathological changes induced by cerebral ischemic injury.

**PTH down-regulated inflammatory mediators in MCAO rats**

qRT-PCR results (Fig. 3A-D) showed that the mRNA expression levels of three proinflammatory cytokines (IL-1β, IL-6, and TNF-α) and one chemokine (MCP-1) in the brains of the MCAO group were distinctly elevated relative to those in the brains of the sham group ($p < 0.01$). Conversely, the levels of these inflammatory mediators in the brains of the MCAO + PTH group were significantly inhibited compared with those in the brains of the MCAO group ($p < 0.01$).

**PTH inhibited microglia and astrocyte activations, and decreased iNOS and COX-2 protein levels in MCAO rats**

To further investigate the effects of PTH on neurinflammation in MCAO rats, the levels of Iba-1 and GFAP, the respective microglia- and astrocyte-specific markers, as well as two inflammatory proteins iNOS and COX-2 in the brain were measured in this study. Immunofluorescent staining results (Fig. 4A-B) demonstrated that Iba-1 positive cells in the MCAO group were markedly increased relative to that in the Sham group ($p < 0.01$). PTH treatment significantly decreased Iba-1 positive cells ($p < 0.01$). Moreover, GFAP protein level in the MCAO group was significantly increased relative to that in the Sham group ($p < 0.01$), whereas PTH treatment significantly suppressed its expression ($p < 0.05$). These data indicated that PTH could inhibit ischemia-induced microglia and astrocyte activations in MCAO rats.
Furthermore, as shown in Fig. 4D and E, rats in the MCAO group showed higher levels of iNOS and COX-2 in the brain tissue than rats in the Sham group ($p < 0.01$), and MCAO rats treated with PTH presented lower levels of iNOS ($p < 0.05$) and COX-2 ($p < 0.01$), further verifying the prominent anti-inflammatory effects of PTH against ischemic stroke.

**PTH suppressed the TLR4 signal pathway**

We measured the protein levels of several key proteins in the TLR4 pathway, namely, TLR4, MyD88, and TRAF6, to investigate the possible mechanism of PTH in inflammatory responses. Western blot analysis results (Fig. 5A–C) revealed that TLR4, MyD88, and TRAF6 protein levels were significantly elevated in the MCAO group ($p < 0.05$ or $p < 0.01$), whereas PTH treatment markedly reduced the elevated levels of these proteins ($p < 0.05$ or $p < 0.01$).

**PTH inhibited the NF-κB and MAPK signaling pathways**

The expression levels of several key proteins in the NF-κB and MAPK pathways were determined to further observe the effect of PTH on the downstream pathways of the TLR4 pathway. Results (Fig. 6A–B) showed that compared with those in control rats, the NF-κB p65 level was increased and the IκBα level was decreased significantly in MCAO rats ($p < 0.05$). These changes were obviously inhibited by PTH treatment ($p < 0.05$ and $p < 0.01$). Meanwhile, we also examined the cytosolic/nuclear translocation of NF-κB p65 by using immunofluorescent staining. As illustrated in Fig. 6C–D, NF-κB p65 was highly expressed in the cytoplasm (green) in the Sham group and was significantly translocated to the nucleus in the MCAO group ($p < 0.05$). However, the nucleus/cytoplasm ratio of NF-κB p65 remarkably decreased after PTH treatment ($p < 0.05$).

Moreover, the protein levels of p-ERK1/2, p-JNK, and p-p38 in the MCAO group had significantly increased compared with those in the Sham group (Fig. 7A–C, $p < 0.01$) but were significantly down-regulated under PTH treatment ($p < 0.05$ or $p < 0.01$).

**TAK-242 did not obviously reinforce the anti-inflammatory effects of PTH on cerebral ischemic injury**

As shown in Fig. 8, combined treatment with PTH and TAK-242 markedly decreased cerebral infarct volume ($p < 0.01$) and reduced neurological deficits ($p < 0.05$, Fig. 8C). These effects were similar to the effects of PTH or TAK-242 treatment ($p > 0.05$). Moreover, the mRNA levels of IL-1β, IL-6, and TNF-α were markedly down-regulated in the groups treated with PTH, TAK-242, and PTH + TAK-242 relative to those of the MCAO group ($p < 0.01$). However, no significant difference was observed between these groups ($p > 0.05$).

Furthermore, similar results for the modulation of the key proteins in the TLR4 pathway were observed (Fig. 9). PTH or TAK-242 treatment markedly decreased the protein levels of TLR4, MyD88, NF-κB p65,
and COX-2 in the brain tissue of MCAO rats, and combined treatment with PTH and TAK-242 did not produce a significant synergistic action compared with treatment with PTH or TAK-242 alone ($p > 0.05$).

**Discussion**

In this study, we found that PTH pretreatment could improve neurological function, and alleviate infarct volume and brain injury after cerebral ischemia-reperfusion injury in rats, which were consistent with our previous study [18]. More importantly, PTH significantly suppressed a variety of severe inflammatory responses such as reducing inflammatory mediator releases and inhibiting microglia and astrocyte activations, and the underlying mechanism was partially related to the TLR4/NF-κB/MAPK pathway.

Ischemic stroke is a complex pathophysiological process that is induced by many factors, among which inflammation plays a crucial role [24]. During ischemia onset, resident microglia and astrocytes were activated, and multiple inflammatory factors including cytokines, chemokines and enzymes were excessively released, which not only aggravate brain injury but also influence brain repair [25, 26]. Therefore, suppressing neuroinflammation and related factors could be a critical therapeutic approach for preventing and treating ischemic stroke. In the current study, we observed that PTH significantly inhibit the activation of microglia and astrocytes in MCAO rats, as indicated by the reduced levels of Iba-1 and GFAP. In addition, PTH not only effectively inhibited the releases of three proinflammatory cytokines (IL-1β, IL-6 and TNF-α) and one chemokine (MCP-1), but also decreased the levels of two enzymes (iNOS and COX-2) in the brain. These data allude to the fact that PTH possess a comprehensive anti-neuroinflammatory potential in ischemic stroke.

TLR4, one of the important innate and adaptive immune cell receptors, has been increasingly considered as a key target in regulating cerebral ischemic injury-induced inflammation [27, 28]. TLR4 is stimulated during ischemia occurrence and further activates the recruitment of MyD88. Subsequently, two parallel signaling pathways including NF-κB and MAPK were activated to induce the release of inflammatory mediators [29, 30]. Several previous studies have demonstrated the anti-inflammatory effect of PTH in hepatitis and arthritis, and NF-κB signaling is the current hotspot [20, 21]. However, few studies concentrated on the anti-inflammatory effect of PTH in the TLR4 signaling pathway after ischemic stroke. Therefore, we determined the TLR4 and its related downstream pathways in this study. Our results showed that the protein levels of TLR4, MyD88, and TRAF6 in MCAO rats were significantly elevated and that PTH effectively inhibited the up-regulation of these proteins, indicating that the TLR4 signaling pathway may participate in this effect. Many studies suggested that TLR4-mediated NF-κB activation is of great significance to regulating inflammatory mediators related with cerebral ischemic injury, and its inhibition could reduce infarct volume and improve neurological function in MCAO mice [31]. In addition, ERK1/2, p38 and JNK in the MAPK signaling pathway were activated by TLR4, and the inhibitions of these three subgroups could produce a potential neuro-protective effect in ischemic stroke [12]. In this study, we found that PTH significantly decreased the p65 level and increased the IκBα level, and remarkably decreased the nucleus/cytoplasm ratio of NF-κB p65 in MCAO rats. Meanwhile, PTH also significantly decreased the protein levels of p-ERK1/2, p-p38, and p-JNK. All these indicated that the NF-
κB and MAPK signaling pathways, the two important downstream signal pathways of TLR4, are also involved in the anti-inflammatory effect of PTH.

In addition, the TLR4 small-molecule inhibitor TAK-242 was used in this study to further investigate whether the TLR4 pathway mediated the anti-inflammatory effects of PTH. The results exhibited that combined treatment with PTH and TAK-242 significantly down-regulated the protein levels of TLR4, MyD88, NF-κB p65, and COX-2; inhibited the releases of IL-1β, IL-6, TNF-α, and MCP-1; alleviated cerebral infarct volume; and improved neurological deficits in MCAO rats. However, these alterations were not significantly different from those induced by individual treatment with PTH or TAK-242. Collectively, these results strongly suggested that the TLR4/NF-κB/MAPK signaling pathway was involved in the anti-inflammatory effects of PTH in ischemic stroke.

Despite the above findings, this study has some limitations. First, inflammatory response is a persistent feature throughout the progression of ischemic stroke. However, our study only investigated the short-term protective effects and potential mechanism of PTH. Thus, a long-term study on PTH (lasting for more than 3 days at least) is necessary in the future. Second, PTH is composed of variety of active compounds with different contents, among which many compounds have diverse pharmacological effects and different molecular targets. Therefore, we believe that the protective effects of PTH should be mediated by more than one molecular target, and additional integrated strategies, such as metabolomics and network pharmacology combined investigation, are warranted.

Conclusions

This study demonstrated that PTH could inhibit neuroinflammation, improve neurological function, and alleviate brain injury in MCAO rats. The potential mechanism of these effects was partially related to the TLR4/NF-κB/MAPK signaling pathway. This study provided fundamental evidence for the potential of PTH as an anti-inflammatory agent against ischemic stroke and will help guide its clinical application.

Abbreviations


Declarations
Acknowledgments

Not applicable.

Ethics approval and consent to participate

All participants provided written informed consent and the protocol was approved by the Animal Care and Use Committee of Fujian University of Traditional Chinese Medicine.

Consent to publish

Not applicable.

Availability of data and materials

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

JL and M-QH contributed to the research conceptualization and design. X-QZ, QZ, L-LH, M-ZL and Z-XC performed the experiments and collected the data. Y-FZ and WX analyzed the data. J-JL supervised the study. X-QZ, QZ and L-LH wrote the draft of the manuscript. All authors read and approved the final manuscript.

Funding

This study was supported by the National Natural Science Foundation of China (81973437), and the School Management Project of Fujian University of traditional Chinese Medicine (X2018013).

Competing interests

The authors declare that they have no competing interests.

References


Figures

Figure 2
Effects of PTH on the cerebral histopathological changes in MCAO rats (n=6). Hematoxylin-eosin-stained slides of the brain sections in different groups were examined under a light microscope. Normal neurons were arranged in a regular manner with intact structure (white arrow). Abnormal neurons exhibited obvious disordered arrangement, nuclei shrinkage and dark staining (red arrow). Scale bar=100 μm.

Figure 3

Effects of PTH on cerebral IL-1β (A), IL-6 (B), TNF-α (C), and MCP-1 (D) mRNA levels in MCAO rats (n=3). Data were presented as mean ±SEM. **P < 0.01 versus Sham; ##P < 0.01 versus MCAO.
Figure 8

TAK-242 did not obviously enhance the anti-inflammatory effect of PTH on cerebral ischemic injury. (A) Representative T2-weighted images of brain sections in different groups (n=6). (B) Quantitative analysis of infarct volume in different groups (n=6). (C) Quantitative analysis of neurological deficits in different groups (n=6). (D-F) Quantitative analysis of IL-1β (D), IL-6 (E) and TNF-α (F) mRNA levels in different groups (n=3). Data were presented as mean ± SEM. **P < 0.01 versus Sham; #P < 0.05, ##P < 0.01 versus MCAO.